Microsoft word - reg bath salts synthetic marijuana 2012.doc
STATE OF CONNECTICUT
DEPARTMENT OF CONSUMER PROTECTION
Section 21a-243-7 of the Regulations of Connecticut State Agencies is amended to read
listed in this regulation are included by whatever official,
common, usual, chemical, or trade name designation in Schedule I:
(a) Any of the following opiates, including their isomers, esters, ethers, salts and salts of
isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:
(1) Acetylalpha-methylfentanyl; (2) Acetylmethadol; (3) Allylprodine; (4) Alphacetylmethadol (except Levo-alphacetylmethadol or LAAM); (5) Alphameprodine; (6) Alphamethadol; (7) Alpha-methylfentanyl; (8) Alphamethylthiofentanyl; (9) Benzethidine; (10) Betacetylmethadol; (11) Beta-hydroxy-fentanyl; (12) Beta-hydroxy-3-methylfentanyl; (13) Betameprodine; (14) Betamethadol; (15) Betaprodine; (16) Clonitazene; (17) Dextromoramide; (18) Diampromide; (19) Diethylthiambutene; (20) Difenoxin; (21) Dimenoxadol; (22) Dimepheptanol; (23) Dimethylthiambutene; (24) Dioxaphetyl Butyrate; (25) Dipipanone; (26) Ethylmethylthiambutene; (27) Etonitazene; (28) Etoxeridine; (29) Furethidine; (30) Hydroxypethidine; (31) Ketobemidone; (32) Levomoramide; (33) Levophenacylmorphan; (34) 3-methylfentanyl; (35) 3-methylthiofentanyl; (36) Morpheridine; (37) Noracymethadol; (38) Norlevorphanol; (39) Normethadone; (40) Norpipanone; (41) Para-fluorofentanyl; (42) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine); (43) Phenadoxone;
(44) Phenampromide; (45) Phenomorphan; (46) Phenoperidine; (47) Piritramide; (48) Proheptazine; (49) Properidine; (50) Propiram; (51) Racemoramide; (52) Thiofentanyl; (53) Tilidine; (54) Trimeperidine.
(b) Any of the following opium derivatives, their salts, isomers and salts of isomers, unless
specifically excepted whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:
(1) Acetorphine; (2) Acetyldihydrocodeine; (3) Benzylmorphine; (4) Codeine methylbromide; (5) Codeine-N-oxide; (6) Cyprenorphine; (7) Desomorphine; (8) Dihydromorphine; (9) Drotebanol; (10) Etorphine, except hydrochloride salts; (11) Heroin; (12) Hydromorphinol; (13) Methyldesorphine; (14) Methyldihydromorphine; (15) Morphine methylbromide; (16) Morphine methylsulfonate; (17) Morphine-N-oxide; (18) Myrophine; (19) Nicocodeine; (20) Nicomorphine; (21) Normorphine; (22) Pholcodine; (23) Thebacon.
(c) Any material, compound, mixture or preparation which contains their salts, isomers and
salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Alpha-ethyltryptamine; (2) 4-bromo-2,5-dimethoxyamphetamine; or 4-bromo-2,5-DMA; (3) 2,5-dimethoxyamphetamine; or 2,5-DMA; (4) 2,5-Dimethoxy-4-ethylamphetamone or DOET; (5) 3,4-M ethylenedioxy-N-ethylamphetamine; (6) 1-methyl-4-phenyl-4-propionoxypiperidine; or MPPP; (7) 3,4-methylenedioxymethamphetamine; or MDMA; (8) 2,5-dimethoxy-4-(n)-propylthiopenenthylamine (2C-T-7); (9) 4-methoxyamphetamine; or PMA; (10) 5-methoxy-3,4-methylenedioxy-amphetamine; (11) 5-Methoxy-nn-Diisopropyltryptamine(5-methoxy-dipt); (12) 4-methyl-2,5-dimethoxyamphetamine; or DOM; or STP (13) 3,4-methylenedioxy amphetamine; or MDA; (14) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA; (15) 3,4,5-trimethoxy amphetamine; (16) benzylpiperazine or BZP; (17) Bufotenine or Mappine; (18) Alphaethyltryptamine; (19) Diethyltryptamine or DET;
(20) Dimethyltryptamine or DMT; (21) Ibogaine; (22) Lysergic acid diethylamide; (23) Marijuana; (24) MDVP (3,4-methylenedioxypyrovalerone); (25) 3,4-methylenedioxy-N-methycathione (methylone) (26) Mephedrone (4-methylmethcathinone); (27) Mescaline; (28) Parahexyl or Synhexyl; (29) Peyote, meaning all parts of the plants; (30) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine; or PEPAP; (31) N-ethyl-3-piperidyl benzilate; (32) N-methyl-3-piperidyl benzilate; (33) Psilocybin; (34) Psilocyn; (35) Tetrahydrocannabinols except Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved product; (36) Salvia divinorum; (37) Salvinorin A; (38) Ethylamine analog of phencyclidine, Cyclohexamine or PCE; (39) 4-Bromo-2,5-dimethoxyphenethylamine; (40) Pyrrolidine analog of phencyclidine, PCP or PHP; (41) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine; (42) Thiophene analog of phencyclidine, TPCP or TCP; (43) Tiletamine or 2-(ethylamino)-2-(2-thienyl)-cyclohexanone; (44) Trifluoromethylphenylpiperazine or TFMPP.
(d) Any material, compound, mixture or preparation which contains any quantity of the
following substances having a depressant effect on the central nervous system, their salts, isomers and salts of isomers unless specifically excepted, wherever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:
(1) Gamma-hydroxy butyric acid, except if contained in a drug product for which an
application has been approved under section 505 of the federal food, drug and cosmetic act;
(2) Gamma-butyrolactone; (3) Mecloqualone; (4) Methaqualone; or (5) Zolazepam.
(e) Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
(1) Aminorex; (2) N-benzylpiperazine (some other names: BZP; 1-benzylpiperazine); (3) 4-Methylaminorex; (4) Cathinone; (5) Fenethylline; (6) Methcathinone; (7) N-ethylamphetamine; (8) N,N-Dimethylamphetamine.
(f) Unless specifically excepted or unless listed in another schedule, any material,
compound, mixture or preparation which contains any quantity of a substance having a psychotropic response primarily by agonist activity at cannabinoid-specific receptors affecting the central nervous system. Specific compounds include, but are not limited to:
(1) 1-pentyl-3-(1-naphthoyl)indole (JWH-018); (2) 1-butyl-3-(1-naphthoyl)indole (JWH-073); (3) 1-[2-(4- morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); (4) 5-(1,1- dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497); (5) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol CP-47,497 C8 homologue).
STATEMENT OF PURPOSE:
Connecticut General Statutes Section 21a-243 permits the Commissioner of
Consumer Protection to classify certain drugs as controlled substances. The purpose of these proposed regulations is to amend existing sections to add certain drugs to the schedules of controlled substances as directed by Public Act 2011-73 and Public Act 2011-210. Drugs listed in these schedules of controlled substances are more highly regulated than other prescription drugs. These drugs have increased security and recording requirements, and violations of the associated laws yield greater criminal penalties. Therefore, the drugs added to the schedules of controlled substances by these proposed regulations will be more highly regulated, which will lead to a higher level of public safety.
The Department’s proposed regulation adds “synthetic marijuana” compounds
and the substances “Salvia Divinorum” and “Salvinorin A” to the list of controlled substances, pursuant to Public Act 2011-73 (Senate Bill 1098)
The proposed regulation also adds Mephedrone (4-methylmethcathinone); and MDPV (3,4-methyenedioxypyrovalerone) to the list of controlled substances, pursuant to Section 3 of Public Act 2011-210 (House Bill 6554). The related drug 3,4-methylenedioxy-N-methycathione (methylone) has likewise been added, per the request of the Department’s Director of Drug Control, as the Federal Drug Enforcement Administration has recently designated this drug as a Schedule I controlled substance via its emergency scheduling authority. These substances, commonly known as bath salts, have recently been the focus of drug abuse.
(C) Legal Effects:
These proposed regulations alter the list of controlled substances set forth in
section 21a-243-7 of the current regulations. The updates are due to statutory changes.
Amended as hereinabove stated
of the General Statutes and
of the General Statutes, as amended by Public Act No. 73
of the 2011
of Public Act No. 210
of the 2011
After publication in the Connecticut Law Journal on ________________ of the notice of the proposal to:
And the holding of an advertised public hearing on _______ day of _______________ 20 ____
WHEREFORE, the foregoing regulations are hereby:
Amended as hereinabove stated
When filed with the Secretary of the State.
The ___________ day of ___________________ , 20 _______.
SIGNED (Head of Board, Agency or Commission)
legal sufficiency in accordance with Sec.
Disapproved in part, (Indicate Section Numbers disapproved only)
SIGNED (Clerk of the Legislative Regulation Review Committee)
Committee in accordance with Sec. 4-170,
Two certified copies received and filed, and one such copy forwarded to the Commission on Official Legal Publications in accordance with Section 4-172, as amended, of the General Statutes.
One copy of all regulations for adoption, amendment or repeal, except emergency regulations, must be presented to the Attorney General for his determination of legal sufficiency. Section 4-169 of the General Statutes. Seventeen copies of all regulations for adoption, amendment or repeal, except emergency regulations, must be presented to the standing Legislative Regulation Review Committee for its approval. Section 4-170 of the General Statutes. Each regulation must be in the form intended for publication and must include the appropriate regulation section number and section heading. Section 4-172 of the General Statutes. Indicate by "(NEW)" in heading if new regulation. Amended regulations must contain new language in capital letters and deleted language in brackets. Section 4-170 of the General Statutes.
For international dialling refer to page 213. Entries in the Who’s Who directory are invited from freelance members of BECTU, SIPTU and TEEU. Accuracy and completeness of detail are the responsibility of the contributor within the limits of spaceavailable. Users of Filmscan requiring information should contact the contributors directly. Mary Alleguen Production Manager Tony Boston
ASSOCIATION OF BRITISH NEUROLOGISTS SPRING MEETING, 30 March – 1 April 2005 at Queen’s University, Belfast PROGRAMME Wednesday 30 March 2005 am Committee Meetings Meeting of Clinical Directors and Lead Clinicians Afternoon Session 1 1400 Introduction and Welcome: Dr Stanley Hawkins Topic: Structure of neurological care Chairman: Dr J Morrow S